Biological therapy for psoriasis: An overview of infliximab, etanercept, efalizumab and alefacept

IDrugs

Volumn 7, Issue 1, 2004, Pages 45-49

  Tutrone, William D ^a   Saini, Ritu ^a   Weinberg, Jeffrey M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Arthritis; Biologic therapy; Cytokine; Psoriasis; T cell; Tumor necrosis factor

Indexed keywords

ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; HYBRID PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ABSENCE OF SIDE EFFECTS; BIOLOGICAL THERAPY; CELL MIGRATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; HUMAN; MEMORY T LYMPHOCYTE; NONHUMAN; PSORIASIS; PUSTULAR PSORIASIS; REVIEW; T LYMPHOCYTE ACTIVATION; ANIMAL; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN G; MICE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 1942475166     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Tutrone WD, Kagen MH, Barbagallo J, Weinberg JM: Biologic therapy for psoriasis: A brief history, II. Cutis (2001) 68(6):367-372.
2. Singri P, West DP, Gordon KB: Biologic therapy for psoriasis: The new therapeutic frontier. Arch Dermatol (2002) 138(5):657-663.
3. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet (2001) 357(9271):1842-1847.
4. Schopf RE, Aust H, Knop J: Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab. J Am Acad Dermatol (2002) 46(6):886-891.
5. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Luftl M: Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol (2001) 144(3):587-589.
6. Newland MR, Weinstein A, Kerdel F: Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol (2002) 41(7):449-452.
7. O'Quinn RP, Miller JL: The effectiveness of tumor necrosis factor α antibody (infliximab) in treating recalcitrant psoriasis: A report of 2 cases. Arch Dermatol (2002) 138(5):644-648.
8. Gottlieb AB, Li S, Evans R, Menter A: Infliximab in the treatment of psoriasis: Results from the first 10 weeks of a phase II trial. 61st American Academy of Dermatology Annual Meeting, San Francisco, CA, USA (2003):Abs 596.
9. Chan JJ, Gebauer K: Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-α antibody (infliximab). Australas J Dermatol (2003) 44(2):116-120.
10. Lebwohl M: New developments in the treatment of psoriasis. Arch Dermatol (2002) 138(5):686-688. Good general overview of new treatments for psoriasis and potential future developments.
11. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med (2001) 345(15):1098-1104.
12. Bresnihan B, Cunnane G: Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am (2003) 29(1):185-202.
13. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC: Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis (2003) 3(3):148-155.
14. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum (2002) 46(12):3151-3158. Interesting article describing the incidence of lymphoproliferative disorders in patients administered etanercept or infliximab.
15. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O: Anti-TNF-α-induced systemic lupus syndrome. Clin Rheumatol (2003) 22(1):56-61.
16. Watts RA: Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol(2000) 12(1):49-52.
17. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P: Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet (1999) 354(9194):1932-1939.
18. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF et al: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 117(4):761-769.
19. Shakoor N, Michalska M, Harris CA, Block JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 359(9306):579-580.
20. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet (2000) 356(9227):385-390.
21. Gottlieb AB, Matheson R, Lowe NJ, Zitnik RJ: Efficacy of Enbrel in patients with psoriasis. J Invest Dermatol (2002) 119:Abs 234.
22. Iyer S, Yamauchi P, Lowe NJ: Etanercept for severe psoriasis and psoriatic arthritis: Observations on combination therapy. Br J Dermatol (2002) 146(1):118-121.
23. Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G Nestle FO: Generalised pustular psoriasis induced by cyclosporin A withdrawal responding to the tumour necrosis factor α inhibitor etanercept. Dermatology (2002) 205(2):213-216.
24. Leonardi C, Gottlieb AB, Zitnik R: Efficacy and safety of Enbrel® (etanercept) in patients with psoriasis. International Investigative Dermatology Meeting 2003, Miami Beach, FL, USA (2003):Abs 0409.
25. Weinberg JM, Saini R: Biologic therapy for psoriasis: The tumor necrosis factor inhibitors infliximab and etanercept. Cutis (2003) 71(1):25-29.
26. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med (2003) 138(10):807-811.
27. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu P et al: Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol (2000) 42(3):428-435.
28. Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Quellet JP et al: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol (2001) 45(5):665-674.
29. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M: Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol (2002) 138(5):591-600.
30. Gordon KB, Leonardi C, Tyring S et al: Efalizumab (anti-CD11a) is safe and effective in the treatment of psoriasis: Pooled results of the 12-week first treatment period from 2 phase III trials. J Invest Dermatol (2002) 119:Abs 242.
31. Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med (2001) 345(4):248-255.
32. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE: An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol (2003) 139(6):719-727.
33. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN: A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol (2002) 47(6):821-833.
34. Krueger GG, Ellis CN: Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol (2003) 148(4):784-788.